KARACHI: Nestle Pakistan Limited reported a 3 per cent increase in net profit for the nine months ended 30 September 2026, to Rs14.53 billion from Rs14.10 billion in the corresponding period last year, according to a summary of the company's announcement carried by Mettis Global. In pharmaceuticals, Macter International Limited's consolidated profit after taxation fell 33.98 per cent year-on-year to Rs95.92 million for the quarter ended 30 September 2026, from Rs145.29 million a year earlier, the same summary said.

Two consumer names, two directions

The figures arrived in the same results window and under the same cost environment — elevated energy prices and a policy rate of 11.5 per cent through the period — but they describe different businesses: a food company reporting over nine months and a pharmaceutical company reporting over one quarter. Results periods differ across companies because their financial years and board calendars differ; the PSX announcements list states the period for each filing. Our explainer on earnings season at the PSX explains how to line up periods before comparing companies.

How the business models differ

Nestle Pakistan's business is described in our company explainer on how Nestle Pakistan makes money, which covers its food and beverage segments without any assessment of its shares. Pharmaceutical results, by contrast, are shaped by regulated pricing, raw-material imports and product mix — background covered in our guide to PSX pharmaceutical stocks. Both guides are educational and describe mechanics, not investment merit.

What was not in the summaries

The Morning Breeze summaries carried the headline profit figures only; revenue, margins, earnings per share and any dividend declarations for these two companies were not included in the summaries retrieved for this article, and no dividend is reported here for either company. The full filings are available in the PSX announcements section for each company. This article is educational content, not financial advice.

Reading profit changes in context

A 3 per cent rise in nine-month profit and a 34 per cent fall in one quarter's profit are not directly comparable numbers: the first smooths nine months of trading, the second captures three. Quarterly pharmaceutical results in Pakistan are also affected by the timing of price adjustments and imported raw-material costs, which move with the exchange rate — the rupee was nearly flat through the September quarter's end. The full filings, rather than the summaries, contain the revenue and margin detail needed to attribute either company's change; this article reports the headline figures exactly as summarised from the exchange announcements.

Key takeaway: Nestle Pakistan's nine-month profit rose 3% to Rs14.53bn, while Macter International's first-quarter consolidated profit fell about 34% to Rs95.92m, as summarised from their PSX filings.